Clinical Trial Update: Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of osimertinib and carotuximab in advanced EGFR-mutated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Carotuximab (carotuximab)
• Osimertinib (osimertinib)

Snippet

Sponsor: Karen Reckamp, MD, MS | Conditions: Non Small Cell Lung Cancer, Lung Cancer | Phase 1 | Status: RECRUITING